Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date08 Jun 2023 |
以安慰剂为平行对照评价参味宁郁片治疗抑郁症(气阴两虚证)有效性和安全性随机双盲单模拟、多中心临床试验
[Translation] A randomized double-blind, single-dummy, multicenter clinical trial to evaluate the efficacy and safety of Shenwei Ningyu tablets in the treatment of depression (Qi and Yin deficiency syndrome) with placebo as parallel control
进一步评价参味宁郁片治疗抑郁症(气阴两虚证)的有效性及安全性。
[Translation] To further evaluate the efficacy and safety of Shenwei Ningyu Tablets in the treatment of depression (Qi and Yin deficiency syndrome).
100 Clinical Results associated with Guangdong Siji Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Guangdong Siji Pharmaceutical Co., Ltd.
100 Deals associated with Guangdong Siji Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Guangdong Siji Pharmaceutical Co., Ltd.